🇺🇸 FDA

Company profile · Sponsor

AbbVie

AbbVie Deutschland GmbH & Co. KG

E0ED385 · EMA pharma Wiesbaden, DE
Pipeline
24
Drugs
0
Patents
0

Quick answer

AbbVie (E0ED385) is a pharma company. headquartered in Wiesbaden, DE. listed on EMA. NovaPharmaNews links 24 pipeline programs, 0 drugs, and 0 patents to this profile..

Company facts

Ticker E0ED385
Exchange EMA
Company type pharma
Headquarters Wiesbaden, DE

Pipeline (24)

Search pipeline →

  1. ABBV-066 / Risankizumab, ABBV-066, Entyvio 300 mg powder for concentrate for solution for infusion

    AbbVie

    Ulcerative Colitis

    phase 3 small molecule active

    1 trial

  2. ABBV-066 / Risankizumab, Risankizumab, Matching Placebo for 90 mg solution for injection, ABBV-066, Matching placebo for 180 mg solution for injection

    AbbVie

    Crohn's disease

    phase 3 small molecule active

    1 trial

  3. ABBV-RGX-314 or RGX-314, ABBV-RGX-314 or RGX-314, Lucentis 10 mg/ml solution for injection in pre-filled syringe, Eylea 40 mg/mL solution for injection in pre-filled syringe

    AbbVie

    Neovascular age-related macular degeneration

    phase 3 small molecule active

    1 trial

  4. AZACITIDINE, Venetoclax, Venetoclax, Venetoclax

    AbbVie

    Acute Myeloid Leukaemia

    phase 3 small molecule active

    1 trial

  5. Atogepant

    AbbVie

    Chronic or Episodic Migraine (Migraine without aura, migraine with aura, or chronic migraine)

    phase 3 small molecule active

    1 trial

  6. Atogepant, Placebo for Atogepant

    AbbVie

    Chronic Migraine

    phase 3 small molecule active

    1 trial

  7. Atogepant, Placebo for Atogepant

    AbbVie

    Menstrual Migraine

    phase 3 small molecule active

    1 trial

  8. Atogepant, Placebo for atogepant tablets 60mg

    AbbVie

    Migraine

    phase 3 small molecule active

    1 trial

  9. BEVACIZUMAB, BEVACIZUMAB, Lonsurf 20 mg/8.19 mg film-coated tablets, Telisotuzumab adizutecan, Lonsurf 15 mg/6.14 mg film-coated tablets

    AbbVie

    Metastatic Colorectal Cancer

    phase 3 small molecule active

    1 trial

  10. Bendamustine 100 mg Powder for concentrate for Solution for Infusion, Truxima 100 mg concentrate for solution for infusion, RoActemra 20 mg/mL concentrate for solution for infusion, PREDNISONE BIOGARAN 20 mg, scored tablet, Cyclophosphamide Injection 500 mg., Doxorubicin 2 mg/ml Solution for Injection., Truxima 500 mg concentrate for solution for infusion, Vincristine Sulfate 1 mg/ml solution for injection, Revlimid 5 mg hard capsules, Epcoritamab (GEN3013), Epcoritamab (GEN3013), Revlimid 20 mg hard capsul

    AbbVie

    Follicular Lymphoma

    phase 3 small molecule active

    1 trial

  11. Bimatoprost SR

    AbbVie

    Open-angle Glaucoma, Ocular Hypertension

    phase 3 small molecule active

    1 trial

  12. CARBOPLATIN, CISPLATIN, PEMETREXED, CARBOPLATIN, PEMETREXED, OSIMERTINIB, CISPLATIN, Telisotuzumab adizutecan, OSIMERTINIB, CARBOPLATIN, PEMETREXED

    AbbVie

    Non-Squamous Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  13. CIPROFLOXACIN, Upadacitinib, Upadacitinib, METHOTREXATE, SULFASALAZINE, Upadacitinib, Upadacitinib, DEXAMETHASONE, Upadacitinib

    AbbVie

    Crohn's Disease (CD)

    phase 3 small molecule active

    1 trial

  14. CISPLATIN, CISPLATIN, Telisotuzumab adizutecan, OSIMERTINIB, PEMETREXED, CARBOPLATIN, CISPLATIN, AMIVANTAMAB, AMIVANTAMAB, CARBOPLATIN, CARBOPLATIN, PEMETREXED, OSIMERTINIB, PEMETREXED

    AbbVie

    Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  15. DARATUMUMAB, LENALIDOMIDE, DEXAMETHASONE, LENALIDOMIDE, LENALIDOMIDE, Etentamig, DEXAMETHASONE, LENALIDOMIDE, LENALIDOMIDE, LENALIDOMIDE

    AbbVie

    Multiple Myeloma

    phase 3 small molecule active

    1 trial

  16. DEXAMETHASONE, POMALIDOMIDE, ELOTUZUMAB, CARFILZOMIB, BORTEZOMIB, DIPHENHYDRAMINE, DEXAMETHASONE, POMALIDOMIDE, DIPHENHYDRAMINE, Etentamig, PARACETAMOL, POMALIDOMIDE, BORTEZOMIB, SELINEXOR, PARACETAMOL, POMALIDOMIDE

    AbbVie

    Relapsed or Refractory Multiple Myeloma (RRMM)

    phase 3 small molecule active

    1 trial

  17. Epcoritamab (GEN3013), Revlimid 5 mg hard capsules, Revlimid 20 mg hard capsules, Epcoritamab (GEN3013), Truxima 500 mg concentrate for solution for infusion, Truxima 100 mg concentrate for solution for infusion

    AbbVie

    Relapsed and Refractory Follicular Lymphoma

    phase 3 small molecule active

    1 trial

  18. Gemcitabine 38 mg/ml Concentrate for Solution for Infusion, Revlimid 25 mg hard capsules, Epcoritamab (GEN3013), Epcoritamab (GEN3013), Oxaliplatin 5mg/ml Concentrate for Solution for Infusion, Revlimid 5 mg hard capsules, Gemcitabine 38 mg/ml Concentrate for Solution for Infusion, Truxima 500 mg concentrate for solution for infusion, Revlimid 20 mg hard capsules, Truxima 100 mg concentrate for solution for infusion

    AbbVie

    Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

    phase 3 small molecule active

    1 trial

  19. Humira 20 mg solution for injection in pre-filled syringe, Humira 40 mg solution for injection in pre-filled syringe, Humira 80 mg solution for injection in pre-filled syringe, Humira 40 mg/0.8 ml solution for injection

    AbbVie

    Ulcerative Colitis

    phase 3 small molecule active

    1 trial

  20. Humira 40 mg solution for injection in pre-filled syringe, Risankizumab, Humira 20 mg solution for injection in pre-filled syringe, ABBV-066

    AbbVie

    Juvenile Psoriatic Arthritis

    phase 3 small molecule active

    1 trial

  21. Ibrutinib hard capsule for oral use, Ibrutinib

    AbbVie

    Follicular Lymphoma

    phase 3 small molecule active

    1 trial

  22. Imnovid 3 mg hard capsules, DEXAMETHASONE , Venetoclax, Imnovid 1 mg hard capsules, Imnovid 4 mg hard capsules, Imnovid 2 mg hard capsules

    AbbVie

    R/R Multiple Myeloma

    phase 3 small molecule active

    1 trial

  23. KEYTRUDA 25 mg/mL concentrate for solution for infusion, Livmoniplimab, Carboplatin 10 mg/ml Intravenous Infusion, Pemetrexed medac 500 mg powder for concentrate for solution for infusion, Cisplatin 1mg/ml Injection BP, Budigalimab

    AbbVie

    Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer, Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer, Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer, Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  24. Livmoniplimab, ATEZOLIZUMAB, TREMELIMUMAB, BEVACIZUMAB, Budigalimab, IMFINZI 50 mg/mL concentrate for solution for infusion.

    AbbVie

    Metastatic Hepatocellular Carcinoma (HCC)

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is AbbVie?

AbbVie (E0ED385) is a pharma company. headquartered in Wiesbaden, DE. listed on EMA. NovaPharmaNews links 24 pipeline programs, 0 drugs, and 0 patents to this profile..

What pipeline programs does AbbVie sponsor?

We track 24 ClinicalTrials.gov-linked programs for AbbVie, including ABBV-066 / Risankizumab, ABBV-066, Entyvio 300 mg powder for concentrate for solution for infusion and 23 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does AbbVie company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.